Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

November’s top stories: Phase III trial of sirukumab, Lyrica fails trial

GlaxoSmithKline begins Phase III trial of sirukumab, Pfizer's neuropathic pain drug Lyrica fails Phase III trial, and Seattle begins Phase I/II trial of SGN-CD33A. Drugdevelopment-technology.com wraps up key headlines from November.

Go Top